- Home
- LTRX vs BDTX Comparison
LTRX vs BDTX Comparison
Compare LTRX & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LTRX | BDTX |
|---|---|---|
| Founded | 1989 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.5M | 220.3M |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LTRX | BDTX |
|---|---|---|
| Price | $5.55 | $2.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $5.17 | ★ $10.60 |
| AVG Volume (30 Days) | 299.4K | ★ 1.8M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.38 |
| Revenue | ★ $118,294,000.00 | $70,000,000.00 |
| Revenue This Year | $4.59 | N/A |
| Revenue Next Year | $12.20 | N/A |
| P/E Ratio | ★ N/A | $7.07 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.91 | $1.20 |
| 52 Week High | $5.89 | $4.94 |
Technical Indicators
Market Signals| Indicator | LTRX | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 64.57 | 26.33 |
| Support Level | $4.88 | $2.24 |
| Resistance Level | $5.89 | $3.90 |
| Average True Range (ATR) | 0.31 | 0.29 |
| MACD | 0.09 | -0.16 |
| Stochastic Oscillator | 77.18 | 20.97 |
Price Performance
Historical ComparisonAbout LTRX Lantronix Inc.
Lantronix Inc is a networking company. It provides secure data access and management solutions for the Internet of Things (IoT) and information technology assets. It organizes its products and solutions into three product lines: Embedded IoT Solutions, IoT Systems Solutions, and Software and Services. The IoT System Solutions segment is the key revenue driver for the company. The company serves a diverse range of markets including healthcare, industrial, security, energy, transportation, and government networking. Its primary geographic markets are the Americas, Europe, the Middle East and Africa, and Asia Pacific Japan. The Americas contribute the vast majority of total revenue.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.